Treatment of Acute Ileal Pouchitis
For acute pouchitis, start with ciprofloxacin 1000 mg daily for 2 weeks as first-line therapy, as it is more effective and better tolerated than metronidazole. 1, 2, 3
First-Line Treatment: Antibiotics
Ciprofloxacin is the preferred antibiotic based on the most recent AGA guidelines 1 and ECCO topical review 2. This recommendation is supported by a randomized trial demonstrating ciprofloxacin's superiority over metronidazole, producing greater reduction in the Pouchitis Disease Activity Index (PDAI) score (6.9 vs 3.8, p=0.002) and better symptom control with no adverse effects compared to 33% experiencing side effects with metronidazole 3, 4.
Treatment duration should be 2 weeks, with symptom improvement typically occurring within 48 hours 2.
Alternative First-Line Options
If ciprofloxacin is contraindicated or not tolerated:
- Metronidazole (20 mg/kg/day) - effective but associated with dysgeusia, nausea, and peripheral neuropathy risk 1, 3
- Combination therapy (ciprofloxacin + metronidazole) may be considered for non-responders to single-agent therapy 1
Second-Line Antibiotics
For patients with allergies, intolerance, or inadequate response to ciprofloxacin/metronidazole 1, 2:
- Oral vancomycin
- Rifaximin (though one study showed no superiority over placebo 5)
- Amoxicillin-clavulanate
- Tinidazole
Diagnostic Confirmation Before Treatment
Always confirm the diagnosis with pouchoscopy showing inflammation limited to the pouch body (distinct from anastomotic/suture lines) and rule out secondary causes 1, 2:
- Test for Clostridioides difficile infection
- Exclude NSAID-induced inflammation
- Consider fecal calprotectin ≥460 µg/g as supportive evidence (sensitivity 66.7%, specificity 82.4%) 2
Refractory and Recurrent Disease Management
Chronic Antibiotic-Dependent Pouchitis (≥3 episodes/year)
Use chronic antibiotic therapy at the lowest effective dose (e.g., ciprofloxacin 500 mg daily or 250 mg twice daily) with intermittent gap periods (approximately 1 week per month) or cycle antibiotics every 1-2 weeks to reduce resistance 1.
Alternative: Advanced immunosuppressive therapies for patients intolerant to antibiotics or concerned about long-term antibiotic risks 1:
- Vedolizumab (highest quality evidence - low certainty) 1, 6
- TNF-α antagonists (infliximab, adalimumab, golimumab, certolizumab)
- Ustekinumab, risankizumab, ozanimod, tofacitinib, upadacitinib
Chronic Antibiotic-Refractory Pouchitis
Use advanced immunosuppressive therapies as primary treatment, with vedolizumab as first-line biologic 1, 6. Perform endoscopic evaluation to confirm inflammation and exclude structural disorders (chronic sinus, leak) with cross-sectional imaging (CT/MR enterography) 2.
Common Pitfalls to Avoid
- Do not use probiotics for acute pouchitis treatment - the AGA makes no recommendation due to knowledge gaps 1. Probiotics (De Simone formulation) are only suggested for preventing recurrent episodes after antibiotic-responsive pouchitis 1.
- Avoid long-term ciprofloxacin without monitoring - risk of tendinitis 2
- Avoid long-term metronidazole without monitoring - risk of peripheral neuropathy 2
- Do not assume all pouch symptoms are pouchitis - always exclude C. difficile and other secondary causes 2
- Reassuringly, there is no increased risk of C. difficile in patients on maintenance antibiotics for chronic antibiotic-dependent pouchitis 2